Phathom Pharmaceuticals (PHAT)
(Delayed Data from NSDQ)
$18.30 USD
-1.20 (-6.15%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $18.29 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Phathom Pharmaceuticals, Inc. (PHAT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$23.00 | $28.00 | $12.00 | 17.95% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Phathom Pharmaceuticals, Inc. comes to $23.00. The forecasts range from a low of $12.00 to a high of $28.00. The average price target represents an increase of 17.95% from the last closing price of $19.50.
Analyst Price Targets (6 )
Broker Rating
Phathom Pharmaceuticals, Inc. currently has an average brokerage recommendation (ABR) of 1.43 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.43 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 71.43% and 14.29% of all recommendations. A month ago, Strong Buy made up 71.43%, while Buy represented 14.29%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.43 | 1.43 | 1.43 | 1.43 | 1.43 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
9/6/2024 | Needham & Company | Joseph R Stringer | Moderate Buy | Moderate Buy |
8/28/2024 | Guggenheim Securities | Yatin Suneja | Strong Buy | Strong Buy |
8/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
7/19/2024 | H.C. Wainwright & Co. | Matthew Caufield | Strong Buy | Strong Buy |
6/30/2024 | Goldman Sachs | Paul K Choi | Hold | Hold |
1/25/2024 | Craig-Hallum | Chase Knickerbocker | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.43 |
ABR (Last week) | 1.43 |
# of Recs in ABR | 7 |
Average Target Price | $23.00 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 83 of 253 |
Current Quarter EPS Est: | -1.57 |
PHAT FAQs
Phathom Pharmaceuticals, Inc. (PHAT) currently has an average brokerage recommendation (ABR) of 1.43 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 7 brokerage firms.
The average price target for Phathom Pharmaceuticals, Inc. (PHAT) is $23.00. The current on short-term price targets is based on 2 reports.
The forecasts for Phathom Pharmaceuticals, Inc. (PHAT) range from a low of $12 to a high of $28. The average price target represents a increase of $25.68 from the last closing price of $18.30.
The current UPSIDE for Phathom Pharmaceuticals, Inc. (PHAT) is 25.68%
Based on short-term price targets offered by six analysts, the average price target for Phathom Pharmaceuticals, Inc. comes to $23.00. The forecasts range from a low of $12.00 to a high of $28.00. The average price target represents an increase of 17.95% from the last closing price of $19.50.